Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 2011

View Archived Issues

New epigenetic therapy for aggressive leukemia shows promise in vivo

Novel target and agents explored for treating hypertension

Presentations provide further phase II data on lesinurad in gout

Abatacept shows efficacy in subgroup of patients with lupus nephritis

New beta-secretase 1 inhibitors disclosed by Array BioPharma and Genentech

GLCCI1 gene variants linked to response to inhaled glucocorticoid asthma therapy

Novel kinesin-like protein KIF11 inhibitors presented

Scientists present new MAP kinase p38 inhibitors

Dainippon Sumitomo Pharma reviews activities of second quarter of fiscal year 2011

University of North Carolina team patents novel anisamide-oligonucleotide conjugates

LivTech and Yakult Honsha enter option agreement for LIV-2008 anticancer program

Gilead Sciences and the Cardiovascular Research Foundation start new ranolazine trial

Novel vaccines for human cytomegalovirus infection prepared in Germany

Taisho Pharmaceutical recaps events of second quarter of fiscal year 2011

Corimmun discloses new fusion proteins for cardiovascular diseases

NeurogesX reports encouraging results on NGX-1998 in postherpetic neuralgia

EC grants marketing authorization to orphan drug for adrenal insufficiency in adults

Lilly and Amylin reach agreement to terminate diabetes alliance

Ablynx and Merck Serono enter new Nanobodies collaboration

Salix Pharmaceuticals to acquire Oceana Therapeutics

FDA approves Erbitux for new indication

FDA accepts NDA for vismodegib

Gen-Probe files notice relating to FDA review of Progensa PCA3 assay

Opexa Therapeutics' lead product receives FDA fast track status

BARDA awards contract to RxBio to develop radiomitigant countermeasure drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...